Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The Kenya tuberculosis diagnostics market was valued at USD 138.43 Million in 2025 and is expected to grow at a CAGR of 4.40%, reaching USD 212.93 Million by 2035. The market growth is driven by the high burden of tuberculosis, government investment in the national strategic plan, growing initiatives, and growing demand for drug-resistant TB testing.
Compound Annual Growth Rate
4.4%
Value in USD Million
2026-2035
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Tuberculosis (TB) diagnostics refers to the range of laboratory tests, imaging techniques, and molecular assays used to detect Mycobacterium tuberculosis, the bacterium responsible for tuberculosis, determine the presence of active TB disease, and identify drug resistance to guide appropriate treatment. The market was valued at USD 138.43 Million in 2025, driven by the high burden of tuberculosis, increasing government investment in TB control programmes, expansion of molecular diagnostic testing, and efforts to improve early case detection and treatment initiation.
|
Analysis Type |
Factors |
Example |
|
Market Drivers |
Expansion of decentralized molecular testing and AI-enabled diagnostic infrastructure |
In June 2026, Kiambu County received over KSh 20 million in TB diagnostic equipment, including portable molecular testing technologies and a digital AI stethoscope. |
|
Market Restraints |
Dependence on external funding and persistent gaps in domestic tuberculosis diagnostic financing |
In March 2025, Kenya's Ministry of Health reported GeneXpert cartridge shortages following a temporary suspension of US funding. |
|
Market Opportunities |
Expansion of near-point-of-care molecular testing across underserved and remote healthcare facilities |
In September 2026, the Global Fund selected Kenya among 13 countries for nearly 3 million portable molecular TB tests by the end of 2026. |
The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.
Expansion of Decentralized Testing and AI-Enabled Diagnostic Technologies to Boost the Market Value
The expansion of decentralized molecular testing is strengthening the market by improving access to rapid testing closer to patients. In June 2026, Kiambu County received TB diagnostic equipment worth over KSh 20 million under the NPOC ACCESS initiative, introducing portable molecular testing and a digital AI stethoscope. Additionally, the Global Fund included Kenya among 13 countries selected for the rollout of nearly 3 million near-point-of-care TB tests. These initiatives support diagnostic accessibility and decentralized testing.
Donor Dependence and Persistent Diagnostic Financing Gaps to Limit Market Expansion
The market faces financing constraints due to dependence on external donors and inadequate domestic healthcare allocations. In March 2025, Kenya's Ministry of Health reported supply gaps in GeneXpert cartridges following a temporary suspension of US funding. In September 2026, Daily Nation reported a Sh4.5 billion national TB funding shortfall, highlighting challenges affecting screening access and digital X-ray licensing. These financing limitations threaten procurement continuity, diagnostic infrastructure utilization, and sustainable market expansion.
Expansion of Decentralized Molecular Testing is Likely to Enhance the Market Landscape
The market presents opportunities to expand decentralized molecular testing and improve access to diagnosis in underserved communities. In September 2026, the Global Fund announced that Kenya was among 13 countries selected to roll out nearly 3 million near-point-of-care molecular TB tests by the end of 2026. These portable tests are intended for primary healthcare centers and remote settings, potentially reducing reliance on complex laboratory infrastructure and strengthening diagnostic access across Kenya.
The market is witnessing several key trends, including a shift toward decentralized molecular testing, the adoption of advanced diagnostic technologies, and the integration of AI-enabled screening solutions.
Shift Towards Decentralized Molecular Testing and AI-Enabled Screening to Elevate the Market Growth
The market is witnessing a shift toward decentralized testing and advanced screening technologies to improve early disease detection. InMarch 2026, Kenya’s Ministry of Health reported expanding TB services across all 47 counties through the deployment of molecular diagnostic technologies and ultraportable AI-enabled digital X-ray machines. These initiatives are strengthening diagnostic accessibility, particularly in remote areas, and supporting demand for portable molecular testing platforms and AI-assisted screening solutions.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Molecular Diagnostics are most Likely to Lead the Market by Diagnostics
Molecular diagnostics are gaining importance in the market, supported by government initiatives to improve early detection and expand access to diagnostic services. In March 2026, Kenya’s Ministry of Health reported expanding TB services across all 47 counties through the deployment of molecular diagnostic technologies and AI-enabled digital X-ray machines. The expansion is expected to strengthen diagnostic accessibility, improve case detection, and support timely identification of tuberculosis, reinforcing demand for molecular diagnostic solutions in Kenya.
The key features of the market report include strategic initiatives by leading players. The major companies in the market are as follows:
Qiagen is a global molecular diagnostics and life sciences company specializing in sample preparation, nucleic acid extraction and molecular testing technologies. Its tuberculosis diagnostic portfolio includes QuantiFERON-TB Gold Plus, an interferon-gamma release assay used to identify TB infection, and technologies supporting molecular detection and laboratory-based infectious disease testing. The company serves clinical laboratories, hospitals and research institutions worldwide.
Cepheid, a subsidiary of Danaher Corporation, develops automated molecular diagnostic systems for infectious disease detection. Its GeneXpert platform and Xpert MTB/RIF and Xpert MTB/RIF Ultra assays enable rapid detection of Mycobacterium tuberculosis and rifampicin resistance. The company's cartridge-based testing technology supports decentralized diagnostics.
Eiken Chemical is a Japanese diagnostics manufacturer specializing in clinical laboratory testing, molecular diagnostics and microbiological assays. Its tuberculosis diagnostic portfolio includes the Loopamp MTBC Detection Kit, which uses loop-mediated isothermal amplification (LAMP) technology to detect Mycobacterium tuberculosis. Its technologies support simplified molecular testing and contribute to expanding TB diagnostic capabilities in resource-limited healthcare settings.
Qure.ai is an artificial intelligence healthcare technology company specializing in medical imaging analysis and clinical decision-support solutions. Its qXR platform uses AI algorithms to analyze chest X-rays and identify abnormalities associated with pulmonary tuberculosis. The technology supports large-scale screening, automated triage, and earlier identification of suspected TB cases, particularly in high-burden and resource-constrained healthcare settings.
Other key players in the market include Abbott, Becton, Dickinson and Company (BD), FUJIFILM Holdings Corporation, Molbio Diagnostics Private Limited, F. Hoffmann-La Roche Ltd., and Hain Lifescience GmbH.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Diagnostics
The segment is supported by the increasing adoption of rapid nucleic acid amplification tests for detecting Mycobacterium tuberculosis and rifampicin resistance. Government-led expansion of diagnostic networks, demand for early case identification, and international funding for TB control are strengthening molecular testing accessibility across Kenya.
Market Breakup by Disease Type
Pulmonary tuberculosis diagnostics account for substantial testing demand because pulmonary TB represents the predominant disease presentation and remains central to community screening and case detection programmes. Increasing deployment of sputum-based molecular assays, microscopy and chest radiography is supporting diagnosis, while improved clinical evaluation and specimen-based testing are strengthening detection of extrapulmonary and latent TB infections.
Market Breakup by End User
Hospitals represent an important end-user segment owing to their role in TB screening, clinical diagnosis, treatment initiation, and management of drug-resistant infections. Increasing availability of molecular diagnostic platforms, laboratory infrastructure investments and integrated TB/HIV services are supporting hospital-based testing. Diagnostic laboratories and public health facilities further contribute through confirmatory testing and surveillance activities.
This report is developed through a structured research approach combining secondary research, market assessment, and data validation:
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnostics |
|
| Breakup by Disease Type |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.